[go: up one dir, main page]

DK0764273T3 - Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose - Google Patents

Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose

Info

Publication number
DK0764273T3
DK0764273T3 DK95920305T DK95920305T DK0764273T3 DK 0764273 T3 DK0764273 T3 DK 0764273T3 DK 95920305 T DK95920305 T DK 95920305T DK 95920305 T DK95920305 T DK 95920305T DK 0764273 T3 DK0764273 T3 DK 0764273T3
Authority
DK
Denmark
Prior art keywords
crystallin
alpha
multiple sclerosis
diagnosis
therapy
Prior art date
Application number
DK95920305T
Other languages
English (en)
Inventor
Noort Johannes M Van
Sechel Arianne C Van
Mustapha El Ouagmiri
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tno filed Critical Tno
Application granted granted Critical
Publication of DK0764273T3 publication Critical patent/DK0764273T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95920305T 1994-06-09 1995-06-08 Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose DK0764273T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94201653 1994-06-09
PCT/NL1995/000203 WO1995033997A1 (en) 1994-06-09 1995-06-08 Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis

Publications (1)

Publication Number Publication Date
DK0764273T3 true DK0764273T3 (da) 1999-06-23

Family

ID=8216937

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95920305T DK0764273T3 (da) 1994-06-09 1995-06-08 Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose

Country Status (10)

Country Link
US (1) US20100291119A9 (da)
EP (1) EP0764273B1 (da)
JP (1) JP3558347B2 (da)
AT (1) ATE172304T1 (da)
AU (1) AU696637B2 (da)
CA (1) CA2192468A1 (da)
DE (1) DE69505376T2 (da)
DK (1) DK0764273T3 (da)
ES (1) ES2125618T3 (da)
WO (1) WO1995033997A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504039A (ja) * 1994-10-25 1998-04-14 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療法
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6861403B2 (en) 2000-05-03 2005-03-01 Expressive Constructs, Inc. Method and device for improving protein stability and solubility
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
EP1624886A2 (en) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
US8771689B2 (en) 2006-12-11 2014-07-08 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for ischemia or inflammation
AU2007333600A1 (en) * 2006-12-11 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for inflammation
US20130236509A1 (en) 2010-07-16 2013-09-12 Delta Crystallon B.V. Microparticles comprising a small heat-shock protein
US10034915B2 (en) 2011-06-23 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
WO2014200346A1 (en) 2013-06-14 2014-12-18 Delta Crystallon B.V. Quantification of alpha b-crystallin
WO2014200345A1 (en) 2013-06-14 2014-12-18 Delta Crystallon B.V. Method for antigen-specific tolerance induction in humans using the small heat shock protein alpha b-crystallin.

Also Published As

Publication number Publication date
US20100291119A9 (en) 2010-11-18
JP3558347B2 (ja) 2004-08-25
AU696637B2 (en) 1998-09-17
ES2125618T3 (es) 1999-03-01
CA2192468A1 (en) 1995-12-14
JPH10501888A (ja) 1998-02-17
DE69505376D1 (de) 1998-11-19
EP0764273B1 (en) 1998-10-14
ATE172304T1 (de) 1998-10-15
EP0764273A1 (en) 1997-03-26
DE69505376T2 (de) 1999-04-08
AU2579995A (en) 1996-01-04
WO1995033997A1 (en) 1995-12-14
US20050013824A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
DE69324487D1 (de) Rezeptorbindende region des diphtherietoxius
SE9500566L (sv) L-platta
DK0559795T3 (da) Fremgangsmåder til diagnosticering af kroniske smerter i lænderegionen og halshvrivelsøjlen
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
ATE181422T1 (de) Verfahren zur diagnose von praeklampsie
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE210721T1 (de) Verwendung eines mbp peptides zur herstellung eines medikamentes für die behandlung von multipler sclerose
ATE168135T1 (de) Diagnose von retinoblastoma
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
PT1025849E (pt) Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
PT841939E (pt) Agentes terapeuticos e doencas auto-imunes
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
ATE86633T1 (de) Snrnp-a-antigen und fragmente davon.
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
ATE312914T1 (de) Rdgb-proteine
IT1283899B1 (it) Peptidi e loro usi nella terapia della malattia celiaca
ATE464567T1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
ATE316657T1 (de) Diagnostische und therapeutische verwendung des caps
DE60314497D1 (de) Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten
UA33330A (uk) Спосіб діагностики ендогенної інтоксикації